Skip to main content

Cellzome Extends Target-Discovery Deal With Novartis

NEW YORK (GenomeWeb News) — Cellzome has extended until June 2008 its research agreement with Novartis, the company said yesterday.
Under the terms of the partnership, Cellzome will continue to use its proteomics and pathway mapping experience to identify therapeutic and pharmacological targets to Novartis compounds.
Financial details of the arrangement were not disclosed, but Cellzome said there are “compound development options for both companies in exchange for licenses, milestone payments and royalties.”
The companies first entered their agreement in 2004 and renewed it last year. In 2005 Novartis made a “substantial equity investment” in the privately held company, Cellzome said

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.